Heupink,T.H.; Subramanian,S.; Wright,J.L.; Endicott,P.; Westaway,M.C.; Huynen,L.; Parson,W.; Millar,C.D.; Willerslev,E.; Lambert,D.M.; The publication in 2001 by Adcock et al. [Adcock GJ, et al. (2001) Proc Natl Acad Sci USA 98(2):537-542] in PNAS reported the recovery of short mtDNA sequences from ancient Australians, including the 42,000-y-old Mungo Man [Willandra Lakes Hominid (WLH3)]. This landmark study in human ancient DNA suggested that an early modern human mitochondrial lineage emerged in Asia and that the theory of modern human origins could no longer be considered solely through the lens of the “Out of Africa” model. [Read More]

Scholl-Bürgi,S.; Kapelari,K.; Michel,M.; Pavlic,M.; Streif,W.; Karall,D.;

pädiatrische praxis 2016 8:273-283

Pitterl,F.; Kob,S.; Pitterle,J.; Steger,J.; Oberacher,H.; Systematic toxicological analysis (STA) is an important step in medicolegal investigations of death, poisoning, and drug use. The primary goal is the detection and confirmation of potentially toxic compounds in evidence. This article describes a workflow using non-targeted liquid chromatography tandem mass spectrometry (LC-MS/MS) for reliable compound identification. Tandem mass spectrometry was performed on a low-resolution quadrupole-quadrupole-linear ion trap instrument. Acquired spectra were submitted to automated library search, and positive matches were verified by expert reviewing. [Read More]

Mayerl,C.; DelFrari,B.; Parson,W.; Boeck,G.; Piza-Katzer,H.; Wick,G.; Wolfram,D.; Background: Dupuytren’s disease is characterised by fibrotic nodule and cord formation in the palmar aponeurosis. The pathophysiology of the disease is still unknown, although cell stress and subsequent activation of immune mechanisms seems to be crucial. Materials and methods: Surgically obtained tissue and blood samples of 100 Dupuytren patients were processed by immunohistochemistry, flow cytometry, as well as immunoscope analysis. Macroscopically normal aponeurotic tissue served as control. [Read More]

Hoefer,J.; Akbor,M.; Handle,F.; Ofer,P.; Puhr,M.; Parson,W.; Culig,Z.; Klocker,H.; Heidegger,I.; Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such resistances are not completely understood, partly due to a lack of model systems. In the present study we established three different cellular models of enzalutamide resistance including a cell line with wild type AR (LAPC4), DuCaP cells which overexpress wild-type AR, as well as a cell which has been adapted to long term androgen ablation (LNCaP Abl) and harbors the AR T878A mutation. [Read More]